X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (115) 115
index medicus (83) 83
male (80) 80
female (77) 77
mucopolysaccharidosis (65) 65
child (59) 59
enzyme replacement therapy (47) 47
adolescent (46) 46
mucopolysaccharidosis vi - physiopathology (45) 45
child, preschool (44) 44
enzymes (43) 43
adult (37) 37
genetics & heredity (36) 36
pediatrics (36) 36
animals (28) 28
children (28) 28
mucopolysaccharidoses - physiopathology (27) 27
disease (26) 26
care and treatment (25) 25
enzyme-replacement therapy (24) 24
medicine, research & experimental (24) 24
young adult (24) 24
maroteaux-lamy-syndrome (23) 23
glycosaminoglycans (22) 22
health aspects (22) 22
endocrinology & metabolism (20) 20
genetics (18) 18
medicine (18) 18
treatment outcome (18) 18
infant (17) 17
mucopolysaccharidosis i - physiopathology (17) 17
n-acetylgalactosamine-4-sulfatase - therapeutic use (17) 17
bone-marrow-transplantation (16) 16
disease models, animal (16) 16
glycosaminoglycans - metabolism (16) 16
medicine & public health (16) 16
research (16) 16
glycosaminoglycans - urine (15) 15
maroteaux-lamy syndrome (15) 15
mucopolysaccharidoses (15) 15
mucopolysaccharidoses - complications (15) 15
mucopolysaccharidosis vi - complications (15) 15
mucopolysaccharidosis vi - therapy (15) 15
diagnosis (14) 14
mucopolysaccharidosis iv - physiopathology (14) 14
mucopolysaccharidosis vi (14) 14
mucopolysaccharidosis vi - drug therapy (14) 14
biopharmaceutics (13) 13
follow-up studies (13) 13
mice (13) 13
n-acetylgalactosamine 4-sulfatase (13) 13
age (12) 12
article (12) 12
mucopolysaccharidosis ii - physiopathology (12) 12
multidisciplinary sciences (12) 12
ophthalmology (12) 12
disease progression (11) 11
enzyme replacement therapy - methods (11) 11
hurler-syndrome (11) 11
internal medicine (11) 11
lysosomal storage diseases (11) 11
mucopolysaccharidoses - diagnosis (11) 11
mucopolysaccharidosis vi - diagnosis (11) 11
n-acetylgalactosamine-4-sulfatase - genetics (11) 11
recombinant proteins - therapeutic use (11) 11
abnormalities (10) 10
bone marrow transplantation (10) 10
congenital, hereditary, and neonatal diseases and abnormalities (10) 10
follow-up (10) 10
middle aged (10) 10
mucopolysaccharidosis iii - physiopathology (10) 10
research article (10) 10
analysis (9) 9
biochemistry & molecular biology (9) 9
biochemistry, general (9) 9
disorders (9) 9
gene therapy (9) 9
heart (9) 9
heart - physiopathology (9) 9
human genetics (9) 9
metabolic diseases (9) 9
mucopolysaccharidosis vi - pathology (9) 9
mutation (9) 9
nutritional and metabolic diseases (9) 9
patients (9) 9
phenotype (9) 9
quality of life (9) 9
science (9) 9
transplantation (9) 9
usage (9) 9
animal models (8) 8
echocardiography (8) 8
feline model (8) 8
mucopolysaccharidoses - therapy (8) 8
mucopolysaccharidosis iv - diagnosis (8) 8
mucopolysaccharidosis vi - genetics (8) 8
pharmacology & pharmacy (8) 8
blood-brain-barrier (7) 7
case-control studies (7) 7
cats (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Pediatric Pulmonology, ISSN 8755-6863, 03/2014, Volume 49, Issue 3, pp. 277 - 284
Background The mucopolysaccharidoses (MPS) comprise a group of inherited lysosomal storage disorders characterized by deficiencies in enzymes catalyzing the... 
glycosaminoglycans | pulmonary function | enzyme replacement therapy | spirometry | mucopolysaccharidoses | MORTALITY | TAIWAN | LARONIDASE | EQUATIONS | CHINESE CHILDREN | HONG-KONG | REFERENCE VALUES | RESPIRATORY SYSTEM | PEDIATRICS | Spirometry | Age Factors | Mucopolysaccharidosis IV - complications | Humans | Mucopolysaccharidosis I - physiopathology | Mucopolysaccharidosis VI - complications | Male | Mucopolysaccharidosis III - drug therapy | Lung Diseases - etiology | Forced Expiratory Volume | Young Adult | Mucopolysaccharidosis II - physiopathology | Adult | Female | Mucopolysaccharidoses - complications | Mucopolysaccharidosis VI - drug therapy | Child | Mucopolysaccharidosis VI - physiopathology | Mucopolysaccharidoses - drug therapy | Severity of Illness Index | Mucopolysaccharidoses - physiopathology | Mucopolysaccharidosis III - physiopathology | Treatment Outcome | Lung - physiopathology | Mucopolysaccharidosis IV - drug therapy | Disease Progression | Mucopolysaccharidosis I - complications | Lung Diseases, Obstructive - physiopathology | Mucopolysaccharidosis III - complications | Enzyme Replacement Therapy - methods | Mucopolysaccharidosis II - complications | Mucopolysaccharidosis IV - physiopathology | Mucopolysaccharidosis II - drug therapy | Mucopolysaccharidosis I - drug therapy | Vital Capacity - physiology | Adolescent | Lung Diseases, Obstructive - etiology | Lung Diseases - physiopathology | Respiratory Function Tests | Peak Expiratory Flow Rate | Maximal Midexpiratory Flow Rate | Enzymes | Respiratory tract diseases | Care and treatment | Mucopolysaccharidosis | Glycosaminoglycans | Chemical properties
Journal Article
Molecular Genetics and Metabolism, ISSN 1096-7192, 2008, Volume 94, Issue 4, pp. 469 - 475
Journal Article
Pediatrics, ISSN 0031-4005, 06/2005, Volume 115, Issue 6, pp. e681 - e689
Journal Article
Journal Article
Journal of Inherited Metabolic Disease, ISSN 0141-8955, 02/2010, Volume 33, Issue 1, pp. 51 - 60
Journal Article
Molecular Genetics and Metabolism, ISSN 1096-7192, 09/2017, Volume 122, Issue 1-2, pp. 107 - 112
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e100882
Background: We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI.... 
SYNOVIAL-FLUID | MULTIDISCIPLINARY SCIENCES | DISEASE | HORSES | OSTEOARTHRITIS | IDENTIFICATION | PROTEINS | ENZYME REPLACEMENT THERAPY | JOINT | Growth Plate - pathology | Biological Availability | Male | Tomography, X-Ray Computed | Femur - diagnostic imaging | Spine - drug effects | Dose-Response Relationship, Drug | Pentosan Sulfuric Polyester - pharmacology | Injections, Subcutaneous | Growth Plate - drug effects | Female | Pentosan Sulfuric Polyester - therapeutic use | Mucopolysaccharidosis VI - drug therapy | Mucopolysaccharidosis VI - physiopathology | Movement - drug effects | Drug Administration Schedule | Administration, Oral | Glycosaminoglycans - metabolism | Mucopolysaccharidosis VI - pathology | Rats | Femur - drug effects | Pentosan Sulfuric Polyester - administration & dosage | Cartilage, Articular - pathology | Biomechanical Phenomena | Spine - diagnostic imaging | Animals | Mucopolysaccharidosis VI - metabolism | Cartilage, Articular - drug effects | Pentosan Sulfuric Polyester - pharmacokinetics | Enzymes | Mucopolysaccharidosis | Glycosaminoglycans | Osteoarthritis | Pentosan polysulfate | Pediatrics | Liver | Arthritis | Cartilage | Biomedical materials | Reduction | Rodents | Animal tissues | Dentition | Tumor necrosis factor-TNF | Biocompatibility | Bioindicators | Drug dosages | Urine | Antigens | Abnormalities | Markers | Oral administration | Teeth | Cartilage (articular) | Inflammation | Bioavailability | Injection | Medicine | Side effects | Orthopedics | Bone | Deformation effects | Cost analysis | Cartilage diseases
Journal Article